Niklas Loman

List of Publications by Year
in descending order

78 papers	11,436 citations	94433 37 h-index	76900 74 g-index
80 all docs	80 docs citations	80 times ranked	14710 citing authors

#	Article	IF	Citations
1	Gene-Expression Profiles in Hereditary Breast Cancer. New England Journal of Medicine, 2001, 344, 539-548.	27.0	1,669
2	Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet, The, 2010, 376, 245-251.	13.7	1,596
3	Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet, The, 2010, 376, 235-244.	13.7	1,584
4	Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation. Journal of Clinical Oncology, 2015, 33, 244-250.	1.6	1,473
5	Association of Type and Location ofBRCA1andBRCA2Mutations With Risk of Breast and Ovarian Cancer. JAMA - Journal of the American Medical Association, 2015, 313, 1347.	7.4	390
6	An HIF-1Î±/VEGF-A Axis in Cytotoxic T Cells Regulates Tumor Progression. Cancer Cell, 2017, 32, 669-683.e5.	16.8	352
7	A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptorâ€“negative breast cancer in the general population. Nature Genetics, 2010, 42, 885-892.	21.4	309
8	Efficacy and safety of olaparib monotherapy in germline BRCA1 / 2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy. Gynecologic Oncology, 2016, 140, 199-203.	1.4	252
9	Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk. PLoS Genetics, 2013, 9, e1003212.	3.5	244
10	Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study. Nature Medicine, 2019, 25, 1526-1533.	30.7	218
11	Identification of New MicroRNAs in Paired Normal and Tumor Breast Tissue Suggests a Dual Role for the ERBB2/Her2 Gene. Cancer Research, 2011, 71, 78-86.	0.9	191
12	Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial. Breast Cancer Research and Treatment, 2013, 138, 499-508.	2.5	183
13	Molecular classification of familial non- BRCA1/BRCA2 breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 2532-2537.	7.1	182
14	Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes. Cancer, 1998, 83, 310-319.	4.1	170
15	Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics. Breast Cancer Research, 2010, 12, R42.	5.0	167
16	Identification of Subtypes in Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer Reveals a Gene Signature Prognostic of Outcome. Journal of Clinical Oncology, 2010, 28, 1813-1820.	1.6	145
17	The Sweden Cancerome Analysis Network - Breast (SCAN-B) Initiative: a large-scale multicenter infrastructure towards implementation of breast cancer genomic analyses in the clinical routine. Genome Medicine, 2015, 7, 20.	8.2	129
18	High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer. Breast Cancer Research, 2010, 12, R25.	5.0	123

#	Article	IF	Citations
19	Clinical and molecular complexity of breast cancer metastases. Seminars in Cancer Biology, 2015, 35, 85-95.	9.6	118
20	Pregnancy-associated breast cancer in BRCA1 and BRCA2 germline mutation carriers. Lancet, The, 1998, 352, 1359-1360.	13.7	111
21	Clinical Value of RNA Sequencingâ€“Based Classifiers for Prediction of the Five Conventional Breast Cancer Biomarkers: A Report From the Population-Based Multicenter Sweden Cancerome Analysis Networkâ€”Breast Initiative. JCO Precision Oncology, 2018, 2, 1-18.	3.0	101
22	Interplay between BRCA1 and RHAMM Regulates Epithelial Apicobasal Polarization and May Influence Risk of Breast Cancer. PLoS Biology, 2011, 9, e1001199.	5.6	91
23	Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial. Breast Cancer Research, 2018, 20, 48.	5.0	80
24	Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2mutation carriers. Breast Cancer Research, 2012, 14, R33.	5.0	78
25	Ki67 proliferation in core biopsies versus surgical samples - a model for neo-adjuvant breast cancer studies. BMC Cancer, 2011, 11, 341.	2.6	76
26	Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival. Annals of Oncology, 2015, 26, 81-88.	1.2	75
27	Refinement of breast cancer molecular classification by miRNA expression profiles. BMC Genomics, 2019, 20, 503.	2.8	75
28	Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. Human Molecular Genetics, 2011, 20, 3304-3321.	2.9	68
29	Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research, 2014, 16, 3416.	5.0	57
30	Comprehensive molecular comparison of BRCA1 hypermethylated and BRCA1 mutated triple negative breast cancers. Nature Communications, 2020, 11, 3747.	12.8	53
31	Somatic genetic alterations inBRCA2-associated and sporadic male breast cancer. Genes Chromosomes and Cancer, 1999, 24, 56-61.	2.8	50
32	Common Variants at the 19p13.1 and ZNF365 Loci Are Associated with ER Subtypes of Breast Cancer and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 645-657.	2.5	47
33	DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. PLoS Genetics, 2014, 10, e1004256.	3.5	47
34	High risk of in-breast tumor recurrence after BRCA1/2-associated breast cancer. Breast Cancer Research and Treatment, 2014, 147, 571-578.	2.5	47
35	Co-targeting of the PI3K pathway improves the response of BRCA1 deficient breast cancer cells to PARP1 inhibition. Cancer Letters, 2012, 319, 232-241.	7.2	45
36	Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women. Breast Cancer Research, 2016, 18, 112.	5.0	42

#	Article	IF	Citations
37	The Retinoblastoma Gene Undergoes Rearrangements in BRCA1-Deficient Basal-like Breast Cancer. Cancer Research, 2012, 72, 4028-4036.	0.9	41
38	Cross comparison and prognostic assessment of breast cancer multigene signatures in a large population-based contemporary clinical series. Scientific Reports, 2019, 9, 12184.	3.3	39
39	Transcriptional Profiling of Breast Cancer Metastases Identifies Liver Metastasisâ€“Selective Genes Associated with Adverse Outcome in Luminal A Primary Breast Cancer. Clinical Cancer Research, 2016, 22, 146-157.	7.0	38
40	Cancer incidence in relatives of a population-based set of cases of early-onset breast cancer with a known BRCA1 and BRCA2mutation status. Breast Cancer Research, 2003, 5, R175-86.	5.0	37
41	Immune gene expression and response to chemotherapy in advanced breast cancer. British Journal of Cancer, 2018, 118, 480-488.	6.4	37
42	Prediction of Lymph Node Metastasis in Breast Cancer by Gene Expression and Clinicopathological Models: Development and Validation within a Population-Based Cohort. Clinical Cancer Research, 2019, 25, 6368-6381.	7.0	37
43	The mutational landscape of the <scp>SCAN</scp> â€B realâ€world primary breast cancer transcriptome. EMBO Molecular Medicine, 2020, 12, e12118.	6.9	36
44	Assessing Associations between the AURKA-HMMR-TPX2-TUBG1 Functional Module and Breast Cancer Risk in BRCA1/2 Mutation Carriers. PLoS ONE, 2015, 10, e0120020.	2.5	34
45	Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers. Human Molecular Genetics, 2011, 20, 4732-4747.	2.9	32
46	G Proteins Coupled to Phospholipase C: Molecular Targets of Long-Term Ethanol Exposure. Journal of Neurochemistry, 1991, 56, 2018-2026.	3.9	31
47	Assessment of early response biomarkers in relation to longâ€term survival in patients with HER2â€negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab: Results from the Phase II PROMIX trial. International Journal of Cancer, 2018, 142, 618-628.	5.1	27
48	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. Breast Cancer Research, 2015, 17, 61.	5.0	26
49	Genetic counselling and testing of susceptibility genes for therapeutic decision-making in breast cancerâ€”an European consensus statement and expert recommendations. European Journal of Cancer, 2019, 106, 54-60.	2.8	25
50	Prognostic implications of the expression levels of different immunoglobulin heavy chain-encoding RNAs in early breast cancer. Npj Breast Cancer, 2020, 6, 28.	5.2	25
51	Challenges to the Development of New Agents for Molecularly Defined Patient Subsets: Lessons From BRCA1/2-Associated Breast Cancer. Journal of Clinical Oncology, 2011, 29, 4224-4226.	1.6	23
52	Long-term prognosis of early-onset breast cancer in a population-based cohort with a known BRCA1/2 mutation status. Breast Cancer Research and Treatment, 2014, 144, 133-142.	2.5	23
53	Agreement between molecular subtyping and surrogate subtype classification: a contemporary population-based study of ER-positive/HER2-negative primary breast cancer. Breast Cancer Research and Treatment, 2019, 178, 459-467.	2.5	23
54	Maximum Tolerated Dose and Pharmacokinetics of Paclitaxel Micellar in Patients with Recurrent Malignant Solid Tumours: A Dose-Escalation Study. Advances in Therapy, 2019, 36, 1150-1163.	2.9	22

#	Article	IF	Citations
55	Preexisting Somatic Mutations of Estrogen Receptor Alpha (ESR1) in Early-Stage Primary Breast Cancer. JNCI Cancer Spectrum, 2021, 5, pkab028.	2.9	20
56	Deletion mapping of chromosome segment 11q24-q25, exhibiting extensive allelic loss in early onset breast cancer. International Journal of Cancer, 2001, 92, 208-213.	5.1	18
57	Efficacy versus effectiveness of clinical genetic testing criteria for BRCA1 and BRCA2 hereditary mutations in incident breast cancer. Familial Cancer, 2017, 16, 187-193.	1.9	18
58	Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. Breast Cancer Research and Treatment, 2017, 161, 117-134.	2.5	18
59	Dynamic evaluation of the immune infiltrate and immune function genes as predictive markers for neoadjuvant chemotherapy in hormone receptor positive, HER2 negative breast cancer. OncoImmunology, 2018, 7, e1466017.	4.6	18
60	PAM50 Provides Prognostic Information When Applied to the Lymph Node Metastases of Advanced Breast Cancer Patients. Clinical Cancer Research, 2017, 23, 7225-7231.	7.0	17
61	Reproductive factors in hereditary breast cancer. Breast Cancer Research and Treatment, 1999, 58, 293-299.	2.5	16
62	Clinical Management of Prostate Cancer in Men with BRCA Mutations. European Urology, 2015, 68, 194-195.	1.9	15
63	BRCAsearch: written pre-test information and BRCA1/2 germline mutation testing in unselected patients with newly diagnosed breast cancer. Breast Cancer Research and Treatment, 2018, 168, 117-126.	2.5	14
64	Detection of circulating tumor cells and circulating tumor DNA before and after mammographic breast compression in a cohort of breast cancer patients scheduled for neoadjuvant treatment. Breast Cancer Research and Treatment, 2019, 177, 447-455.	2.5	14
65	Human G-MDSCs are neutrophils at distinct maturation stages promoting tumor growth in breast cancer. Life Science Alliance, 2020, 3, e202000893.	2.8	14
66	High patient satisfaction with a simplified BRCA1/2 testing procedure: long-term results of a prospective study. Breast Cancer Research and Treatment, 2019, 173, 313-318.	2.5	11
67	Breast cancer survival in Nordic BRCA2 mutation carriersâ€"unconventional association with oestrogen receptor status. British Journal of Cancer, 2020, 123, 1608-1615.	6.4	8
68	The state of the art in prediction of breast cancer relapse using cell-free circulating tumor DNA liquid biopsies. Annals of Translational Medicine, 2016, 4, S68-S68.	1.7	8
69	Impact of the first tumor response at eight weeks on overall survival in metastatic breast cancer patients treated with first-line combination chemotherapy. Medical Oncology, 2013, 30, 415.	2.5	7
70	Analysis of Swedish male breast cancer family data: A simple way to incorporate a common sibling effect. , 1998, 15, 201-212.		5
71	Germline mutations in BRCA1 and BRCA2 incidentally revealed in a biobank research study: experiences from re-contacting mutation carriers and relatives. Journal of Community Genetics, 2018, 9, 201-208.	1.2	5
72	Written pretest information and germline BRCA1/2 pathogenic variant testing in unselected breast cancer patients: predictors of testing uptake. Genetics in Medicine, 2019, 21, 89-96.	2.4	5

#	Article	IF	Citations
73	Protein Signature Predicts Response to Neoadjuvant Treatment With Chemotherapy and Bevacizumab in HER2-Negative Breast Cancers. JCO Precision Oncology, 2021, 5, 286-306.	3.0	5
74	Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes. Cancer, 1998, 83, 310-319.	4.1	2
75	Defining the mutational landscape of 3,217 primary breast cancer transcriptomes through large-scale RNA-seq within the Sweden Cancerome Analysis Network: Breast Project (SCAN-B; NCT03430492).. Journal of Clinical Oncology, 2020, 38, 518-518.	1.6	2
76	Phospholipase C Coupled G-Proteins: Molecular Targets of Ethanol. , 1993, , 235-244.		1
77	Abstract OT2-30-01: Nordictrip, a translational randomized phase-3study exploring the effect of the addition of capecitabine to carboplatinum-based chemotherapy in early â€œtriple negativeâ€•breast cancer, ClinicalTrials.gov Identifier: NCT04335669. Cancer Research, 2022, 82, OT2-30-01-OT2-30-01.	0.9	0
78	Abstract P2-08-11: How reliable are biomarkers assessed on a core needle biopsy? A study of paired core needle biopsies and surgical specimens in early breast cancer. Cancer Research, 2022, 82, P2-08-11-P2-08-11.	0.9	0